5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)
Marc Schneidman’s Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010.
Posts Tagged ‘Dicerna Pharmaceuticals Inc (DRNA)’
Hedge Fund and Insider Trading News: David Tepper, Blue Harbour Group, ValueAct Capital, Schmitt Industries, Inc. (SMIT), Continental Resources, Inc. (CLR), and More
Here is how the activist hedge fund fared with its investment in Investors Bancorp, which accounted for 18 percent of its U.S. long assets.
Hedge Fund and Insider Trading News: Millennium Management, Bridgewater Associates, Seagate Technology PLC (STX), Alta Mesa Resources Inc (AMR), H & R Block Inc (HRB), and More
Nomura Holdings Inc., the Japanese brokerage struggling to improve performance overseas, is hiring a money manager from $35 billion hedge fund Millennium Management to help lead...
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
Please follow RA Capital Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about RA Capital Management or update its stock...
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
Please follow RA Capital Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about RA Capital Management or update its stock...
13G Filing: EcoR1 Capital and Dicerna Pharmaceuticals Inc (DRNA)
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Oleg Nodelman's EcoR1 Capital filed an amended 13D.
You can check out EcoR1 Capital's latest holdings and filings here.
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
Please follow RA Capital Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about RA Capital Management or update its stock...
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
Please follow RA Capital Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about RA Capital Management or update its stock...
13D Filing: Bain Capital Life Sciences Fund, L.P. and Dicerna Pharmaceuticals Inc (DRNA)
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240....
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)
You can access the original SEC filing by clicking here.
Micro-Cap Biotech Focus: Dicerna Pharmaceuticals Inc (DRNA) Presents Its Exciting New Drug Platform GalXC
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is a biopharmaceutical company that focuses on a technology called RNA interference (RNAi).
RA Capital Is Expecting A Breakthrough Cardiovascular Drug From This Biotech
The biotechnology industry is up by more than 50% over the last year, but these towering returns don't come without great risk and volatility.
Entegris Inc (ENTG), Dicerna Pharmaceuticals Inc (DRNA): GMT Capital and Deerfield Management Report Their Latest Moves
In two new filings, Thomas E. Claugus' GMT Capital disclosed further raising its exposure to Entegris Inc (NASDAQ:ENTG).
Ra Capital Management Revealed Stake in Dicerna Pharmaceuticals Inc (DRNA) After Deerfield and Brookside
Ra Capital Management, a fund managed by Peter Kolchinsky, disclosed, in a new filing with the Securities and Exchange Commission, that it owns 2.43 million shares of Dicerna ...
Deerfield Management & Brookside Capital Revealed Significant Stakes in Newly Public Dicerna Pharmaceuticals Inc (DRNA)
In a couple of filings with the Securities and Exchange Commission, Deerfield Management, led by James E.
Hedge Fund Resource Center
